A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

The PARP inhibitor Lynparza improves survival and delays disease progression in men with metastatic castration-resistant prostate cancer that expresses certain gene mutations inhibiting DNA repair, a ...

Genetic studies of prostate cancer susceptibility have predominantly focused on non-Hispanic white men, despite the observation that Black men are more likely to develop prostate cancer and die from ...

In metastatic prostate cancer, defects in DNA damage response genes are now established predictors of benefit to US Food and Drug Administration–approved poly (ADP-ribose) polymerase inhibitors and ...

A transcriptome analysis of castration resistant prostate cancer metastases in a prospective cohort study reveals high expression of AKT pathway genes predictive of long term response to abiraterone ...

Phase 3 trial findings showed that treatment with Lynparza delayed disease progression by about four months compared with newer hormonal agents in pre-treated patients with metastatic ...

"Men with these known variants should be counseled on the increased risk of prostate cancer, and I would recommend that they undergo regular PSA screening…Of course there are many other factors that ...